Physician profile
Ayla Kessler
NPI 1437359585
$4,368.87
in general payments reported to CMS, 2019-2025
41 companies · $944 in 2025
The $944 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,227 · 2020: $537 · 2021: $285 · 2022: $179 · 2024: $197 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.84 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $903.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $424.22 | 2019-2025 | |
| Incyte Corporation | $292.15 | 2019-2025 | Jakafi, Niktimvo |
| Merck Sharp & Dohme LLC | $274.64 | 2019-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $245.28 | 2019-2025 | Imfinzi, Tagrisso |
| Celgene Corporation | $179.11 | 2019-2025 | Reblozyl, Breyanzi |
| Astellas Pharma US INC | $165.04 | 2019-2025 | Xtandi |
| Lilly USA, LLC | $154.66 | 2019-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $147.80 | 2019-2025 | |
| Genentech USA, INC. | $145.61 | 2019 | |
| Seagen INC. | $140.96 | 2019-2022 | |
| Eisai INC. | $109.72 | 2019-2020 | |
| Tempus Ai, INC | $86.55 | 2025 | Xt Cdx |
| Janssen Biotech, INC. | $77.62 | 2019-2025 | Rybrevant |
| Beone Medicines USA, INC. | $72.66 | 2025 | Brukinsa, Tevimbra |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayla Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.